Organon & (US:OGN) GlobeNewswire News Roomยท2025-07-06 11:40Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Organon & Co. due to misleading statements regarding its capital allocation strategy, particularly concerning dividends and debt reduction following the acquisition of Dermavant [3][5]. Group 1: Legal Investigation and Class Action - A federal securities class action has been filed against Organon, with a deadline of July 22, 2025, for investors to seek the role of lead plaintiff [3]. - Investors who suffered losses exceeding $75,000 in Organon between October 31, 2024, and April 30, 2025, are encouraged to contact the firm to discuss their legal rights [1][3]. Group 2: Financial Impact and Stock Performance - Organon provided positive statements about its capital allocation strategy, emphasizing regular dividends as a top priority, while concealing adverse facts about its financial priorities [5]. - Following the revelation of these misleading statements, Organon's stock price dropped from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in one day [6].